Sio Gene Therapies founder Vivek Ramaswamy (JPM20)
A year and a half ago, Sio Gene Therapies attempted to steer into a new history, with then-CEO Pavan Cheruvu telling Endpoints News it was ‘not a vant any longer’ after breaking away from the Axovant name, of the Roivant descent.
The company might be getting a rebrand again soon. That is: Sio is looking for a new owner, or another company to merge with as the biotech is shuttering work on its two remaining programs, for GM1 and GM2 gangliosidosis, or Tay-Sachs and Sandhoff disease.
